How Early-Phase Companies Can Reduce Risks And Future-Proof Their Cell Therapies With Advanced Process Analytics

By Eytan Abraham, Ph.D., VP and Business Head of Cell Therapy, Gene Therapy and Nucleic Acid Franchises, and Bruce Thompson, Ph.D., VP and Technical Head of Cell Therapy Franchise

Cell therapies are probably the most complex therapeutics in development today. They are inherently a ‘living drug’ that interacts with and responds to the ex-vivo (during manufacturing) and in-vivo (post-patient infusion) environments.

Given the complexity, we recommend coordinating most of the process and analytical development, as well as the GMP manufacturing elements, with partners who have the expertise, equipment, and facilities to execute the manufacturing component. Working with a partner such who has these capabilities, resources, and expertise can mitigate risk, costs, and timelines.

Understand more about handling autologous and allogeneic therapies and what to seek in a CDMO partner.